Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services
December 17 2019 - 9:15AM
Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a
medical technology company commercializing sugarBEAT®, a
non-invasive and flexible continuous glucose monitor (CGM),
together with BEAT®diabetes, a health subscription service designed
to help people with diabetes and prediabetes through personalized
lifestyle coaching, today announced a partnership with the
award-winning UK-based company Changing Health to bring digital
behavior programs to improve the management, reversal and
prevention of Type 2 diabetes in multiple territories commencing
with the United Kingdom and Ireland. Changing Health is a provider
of digital coaching services to the National Health Service England
aimed at the prevention or reversal of Type 2 diabetes.
The partnership will utilize CGM data and daily
glucose trend data provided by Nemaura’s non-invasive
sugarBEAT® CGM, combined with Changing Health’s evidence based
digital health coaching solution, which has been the subject of
multiple peer reviewed journal articles demonstrating proven
outcomes in the reduction of HbA1c and weight loss.
The collaboration with Changing Health is one of
a number of initiatives Nemaura is embarking upon, as it seeks to
improve how people with diabetes and prediabetes can manage,
reverse and prevent Type 2 diabetes through its BEAT®diabetes
health subscription service coupled with its non-invasive
sugarBEAT® CGM across the digital health, wearable health-tech and
diabetes sectors.
Dr. Faz Chowdhury, CEO of Nemaura, commented:
“We are delighted to enter into this collaboration with Changing
Health, a leading global force in behavioral change programs. This
collaboration is part of our continued commitment to add further
services to our BEAT®diabetes program aimed at improving management
of diabetes and reversing or preventing Type 2 diabetes.”
Professor Mike Trenell, Founder & Chairman
at Changing Health, said: “This is an exciting collaboration, which
we believe will become a disruptive force in the world of med-tech.
Empowering people with Type 2 diabetes with a real-time view of how
they’re managing their condition each day is the best motivator
there can be, and we’re looking forward to working with Nemaura to
create positive behavioral change at scale.”
About Nemaura Medical, Inc.:
Nemaura Medical, Inc. (NMRD), is a medical technology company
commercializing BEAT®diabetes, a health subscription service
designed to help people with diabetes and prediabetes better manage
diabetes, and reverse type 2 diabetes or prevent diabetes through
1-on-1 lifestyle coaching and behavior driven by real time
continuous glucose monitoring (CGM) and daily glucose trend data
provided by sugarBEAT®, a non-invasive and flexible CGM.
For more information visit:
www.NemauraMedical.com.
About Changing Health
Changing Health provides award-winning programmes and technology
to create behavior change at scale. Our current programs for weight
management, Type 2 diabetes management and Type 2 diabetes
prevention combine one-on-one health coaching, rooted in behavioral
psychology, with digital education tailored to the user’s own
needs. This approach enables healthcare organizations around the
world to deliver highly personalized support and improve outcomes
at scale, making the most of scarce time and resources.
Changing Health is also partnering with NHS England to deliver
the roll out of digital NHS support for up to 600,000 people with
Type 2 diabetes, and is one of the five digital providers on the
NHS Healthier You Diabetes Prevention Programme (DPP).
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura’s ongoing studies,
including the safety and efficacy of Nemaura’s
sugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura and its partners’ ability to
develop, market and sell sugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to sugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
Contact: Crescendo Communications, LLC
212-671-1021 NMRD@crescendo-ir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024